Aim To examine if optimal clopidogrel therapy following percutaneous coronary intervention (PCI) differed systematically by sociodemographic characteristics during and after special authority (SA) restrictions, which required hospital-specialist approval for full funding.
Clopidogrel is an antiplatelet agent that, when combined with aspirin, has greater efficacy in reducing the risk of coronary thrombosis following percutaneous coronary intervention (PCI) than aspirin alone. 1, 2 Delays in clopidogrel therapy post-PCI are associated with worse clinical outcomes. [1] [2] [3] [4] The use of clopidogrel in the 6 months following PCI was standard practice in New Zealand from 2006 until a newer agent, ticagrelor, became available in mid-2012.
Clopidogrel required special authority (SA) approval from the Pharmaceutical Management Agency of New Zealand (PHARMAC) for fully-funded therapy until 1 September 2010, when this restriction was lifted. These criteria specified that patients who had undergone a stent insertion in the preceding four weeks were eligible for 6 months of funded clopidogrel therapy. (See Appendix 1 for the complete SA criteria for clopidogrel. See all Appendices at http://www.nzma.org.nz/journal/read-thejournal/all-issues/2010-2019/2015/vol-128-no-1411/6478/appendices.pdf).
SA applications were completed by hospital clinicians at or prior to hospital discharge. However, the application and prescribing process used to access fully-funded clopidogrel was inconsistent across the country. The application could either be made electronically or on a hard copy form which was faxed or mailed to the Ministry of Health. If the application was completed electronically, the SA number was potentially available before discharge. a clopidogrel prescription to fill once the special authority number was available or may have been advised to see their GP to have it prescribed.
Demographic groups whose health is most vulnerable and who are in greatest need of adequate healthcare are often least likely to receive it. 5 The existence of barriers to equitable healthcare access, such as financial factors, health literacy and institutionalised racism are well documented. 6 The multiple and variable steps required for each patient to receive a fully-funded clopidogrel prescription with the appropriate approval number are another potential impediment to optimal maintenance post-PCI. Our aim was to explore whether the SA requirements implemented in New Zealand represented a barrier that resulted in differential access to clopidogrel by sociodemographic status.
Methods
Study population-All New Zealanders with publicly-funded admissions for PCI who were discharged between 1 July 2009 and 31 December 2009 (while SA criteria for clopidogrel were applicable) and from 1 September 2010 to 28 February 2011 (after removal of SA requirements) were included. The 1 July 2009 to December 2009 time period was chosen to allow at least 6 months of follow-up prior to the 1 September 2010 removal of the funding restriction. In the instance that an individual had multiple admissions during the periods of interest, the first admission was used. The following hospital discharge procedural codes were used to identify patients discharged from hospital following PCI:
• ICD10-AM version 3: 3530400, 3530500, 3531000, 3531001, 3531002.
• ICD10-AM version 6: 3830000, 3830300, 3830600, 3830601, 3830602.
All patients who died as inpatients were excluded.
Data sources-Over 98% of New Zealand residents have a National Health Index (NHI) number that uniquely identifies them within the New Zealand health system. 7 Encrypted NHI numbers were used to anonymously link hospitalisation, mortality, pharmaceutical claims and NHI databases. The pharmaceutical claims database (PHARMS) is administered by the New Zealand Ministry of Health, and collects data on government-subsidised medications dispensed by community pharmacies nationwide. 8 From 2009 onwards, more than 96% of PHARMS data were reliably identifiable by NHI numbers. The NHI database contains patient demographic information and, together with the mortality and hospitalisation datasets, is also administered by the New Zealand Ministry of Health.
Main outcome of interest-Clopidogrel use in the 6 months following hospital discharge for PCI was assessed by calculating a medicine possession ratio (MPR) for each patient. The MPR was derived from the number of days that the patient was dispensed clopidogrel post-discharge divided by the number of days from the start until the end of the follow-up period or until date of death, whichever came first. Days spent in hospital were not included as medications dispensed for inpatients do not require special authority approval.
For patients dispensed clopidogrel in the 90 days prior to hospitalisation, the number of supply days remaining at the time of admission was added to the numerator of the MPR. Optimal clopidogrel dispensing was defined as a MPR > 0.8 (i.e. the patient had clopidogrel in their possession for at least 80% of the 6-month period following discharge).
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Other variables-Age, sex and ethnicity data were obtained from the NHI database. Age was stratified according to 10-year intervals. Ethnic groups were defined according to the New Zealand Ministry of Health's Ethnicity Data Protocols for the Health and Disability Sector. 10 Ethnic groups of interest were: Māori (Level 2 code 21), Pacific (Level 2 codes 30-37), Indian (Level 2 code 43), and Other (Level 2 codes 10-12, 40-42, 44 and 51-99). The 'Other' group are mainly European New Zealanders. Quintiles of deprivation, according to the New Zealand Index of Deprivation 2006 (NZDep06) scores, were used to approximate socioeconomic status. NZDep06 is a census-based index of deprivation for small areas that uses population census data relating to eight dimensions of deprivation.
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Statistical analysis-For the periods during and after SA restrictions,, binomial regression modelling was used to estimate relative risks (RR), with 95% confidence intervals (CI), of having a MPR >0.8 following PCI for each of the sociodemographic characteristics considered. Two-sample t-tests using a 95% level of significance were used to evaluate whether the proportions of patients dispensed clopidogrel and after funding restrictions changed significantly. Data was analysed using STATA 10.0 statistical software. The baseline characteristics for the remaining patients discharged following PCI during the last 6 months of 2009 (n=2416) and in the 6 months immediately following removal of SA restrictions (n=2347) are detailed in Table 1 .
Results

Between
As expected, the characteristics of patients discharged during the two periods were similar. In each discharge group, around three-quarters of patients were aged between 45 and 75 years, men comprised more than 70% of the study population and Māori, Pacific and Indian groups accounted for around 15% of discharges. Patients within each 6-month period were relatively evenly spread across quintiles of deprivation. Figure 1 shows the proportions of patients discharged during and after SA restrictions who had an optimal MPR (i.e. MPR>0.8), a suboptimal MPR (i.e. 0<MPR<0.8) or who received no clopidogrel following discharge. The change in proportions between the two discharge periods was significant (p<0.05) for patients in each of the three categories of dispensing considered. Overall, 74% (95% CI 72%-75%) of patients had a MPR>0.8 while clopidogrel SA criteria were in place compared with 81% (95% CI 79%-82%) of hospital discharges once funding restrictions were lifted. In both discharge periods, 2-3% of patients received no clopidogrel following discharge. Table 2 shows the breakdown of patients who received no clopidogrel in the first and second 3-month periods after discharge. Patients required successful completion of the SA process in order to receive clopidogrel in the first 3-month period. Irrespective of funding restrictions, the proportion of patients who received no clopidogrel was similar in the first 3 months and the entire 6-month period but increased during the second 3 months after discharge. Table 3 presents the numbers and proportions of people with MPRs>0.8, and adjusted RRs with 95% CI according to age, sex, deprivation and ethnic group. Crude RRs are not presented as they were not appreciably different to the adjusted RRs.
The proportion of patients with optimal clopidogrel dispensing improved across all sociodemographic strata once SA requirements were lifted. These increases were statistically significant (p<0.05) for all groups except those aged 55-64 years, patients over 75 years of age and for Pacific patients.
Across the sociodemographic characteristics examined, Māori and Pacific patients had the lowest proportion with a MPR > 0.8 irrespective of whether SA criteria were in effect. However, optimal therapy increased by 12% for Māori patients and 8% for Pacific patients after funding restrictions ended, with increases also noted for the Indian group (16%) and Other patients (6%).
The relative comparison between age groups and by sex showed no clinically relevant differences in the likelihood of optimal clopidogrel dispensing during either discharge period.
Minimal differences in dispensing by deprivation status were noted while funding restrictions were in place. Compared with quintile 1, optimal clopidogrel dispensing was 8% less likely among patients in quintile 3 (RR 0.92, 95%CI 0.86-0.99) and 10% less likely among quintile 4 patients (RR 0.90, 95%CI 0.84-0.97). No significant dispensing differences were found after SA criteria were lifted.
Compared with the 'Other' group, Māori patients had a 14% lower likelihood of optimal clopidogrel dispensing (RR 0.86, 95% CI 0.76-0.97) and Pacific peoples were 13% less likely (RR 0.87, 95%CI 0.73-1.02) while funding restrictions were in place. These findings did not change appreciably following removal of SA requirements. 
Discussion
Among patients who had undergone publicly-funded PCI across New Zealand, optimal clopidogrel coverage in the 6 months following hospital discharge increased from 74% to 81% once SA criteria were lifted, with improvement noted across all sociodemographic strata.
Only 2-3% of patients in both discharge periods received no clopidogrel therapy during follow-up. However, Māori and Pacific peoples were the most undertreated post-PCI. Removal of SA requirements did not change relative ethnic differences to any extent, despite absolute increases in optimal dispensing for all ethnic groups. Smaller relative differences in clopidogrel dispensing were noted by age, sex and deprivation status, irrespective of whether SA criteria were in place.
Our study included all publicly-funded acute and elective hospital admissions for PCI recorded across New Zealand during the last half of 2009 and between September 2010 and February 2011. The proportion of all PCIs that are performed in the private health sector is currently unknown, but is likely to be in the order of 10-20% for both the discharge periods considered in this study.
All data were obtained through routinely collected and relatively comprehensive national health databases, which aids the generalisability of the findings. Data regarding dispensed medications were abstracted from a nationwide database recording medications dispensed by community pharmacists. This minimised the potential for misclassification error based on patient self-report or incomplete health provider records.
Our analyses are based on observational data, and a systematic change in clinical practice over time could have contributed to the improvement in dispensing after SA criteria were lifted. This is unlikely, however, since there was no change to national or international guidelines regarding clopidogrel use post-PCI over the study period, or introduction of quality or performance incentives associated with guideline adherence. Furthermore, the increase in dispensing after SA removal could not be accounted for by changes in clopidogrel dispensing patterns over time. (See Appendix 2 for the monthly proportions of the study population who received no clopidogrel and optimal therapy between July and December 2009 and between September 2010 and February 2011).
We could not identify whether patients actually took medications that were dispensed to them, though this is a minor limitation since our focus was to determine if SA criteria differentially restricted access to medications by sociodemographic status. We also did not consider re-admission during follow-up, or exclude the very small number of non-New Zealand residents who received publicly-funded PCIs and who may have left the country post-procedure. The latter may comprise part of the patient group who were not dispensed any clopidogrel following discharge.
Few other studies have been published regarding the effect of funding restrictions on the sociodemography of patients accessing medications. Ostini et al explored clopidogrel use in Australia using anonymised routinely collected data for Queensland and New South Wales. Clopidogrel use following stenting was associated with being older and male sex, in contrast with our findings of minimal differences in clopidogrel coverage post-PCI by age and sex. 12 However, stenting was not a government-subsidised indication for clopidogrel prescription in Australia at the time of publication so financial barriers would have been greater than in our study and utilisation by ethnicity or socioeconomic status were not examined.
We noted an absolute improvement in optimal dispensing by 7% across all sociodemographic groups once SA criteria were removed, which is supported by evidence that restricted funding policies for clopidogrel have detrimental effects on therapy following discharge.
A Canadian study of 13663 patients who underwent stenting between January 2000 and September 2004 found that restricted access to clopidogrel resulted in a lack of filling at least one prescription following hospitalisation or delays in this process in around 20% of patients. 13 However, this proportion is not directly comparable to our results as we used optimal coverage post-discharge rather than a binary measure of prescription-filling, and we did not examine therapeutic delays directly.
Another Canadian study also noted negative effects on clopidogrel prescription-filling among 112 patients post-stenting in Alberta as a result of a prior authorisation process. 14 The association between restrictive reimbursement policies and lower rates of medication utilisation has also been noted for a range of other medications [15] [16] [17] [18] [19] , although dispensing by demographic characteristics was not examined.
While funding restrictions applied, only 3% of patients received no clopidogrel therapy in the 3 months after discharge (Table 2) indicating that the SA process was successfully completed for almost all patients in our study population within this time-frame. Nevertheless, administrative errors or delays, and general confusion about the process among patients and health professionals are likely to have contributed to the reduced clopidogrel coverage associated with the prior approval policy. However, the use of clopidogrel as part of a routine clinical pathway following PCI was probably a protective factor, without which the SA process may have even further restricted access.
Our analyses showed sub-optimal clopidogrel coverage for Māori and Pacific patients post-PCI relative to other ethnic groups which remained after funding restrictions were lifted. Inadequate maintenance of other CVD medications has also been observed across New Zealand among Māori and Pacific peoples. Among a national cohort of 11 348 patients aged 35 to 84 years of age who were discharged from hospital with Acute Coronary Syndrome in 2007, Māori and Pacific patients were 13-25% less likely to have a statin MPR>0.8 as compared with the European/Other group. 20 A number of factors could be relevant in the undertreatment of Māori and Pacific patients including language or other cultural barriers, and variation in prescribing practices by ethnicity which may result in differential utilisation of medications. 6, [21] [22] [23] It would be useful to explore the factors influencing clopidogrel use following PCI among different ethnic groups, and particularly whether sub-optimal coverage is related to health professional behaviour, other factors such as hospital readmission or patient-related barriers to filling clopidogrel prescriptions. The influence of SA requirements on clinical outcomes is also relevant, given evidence suggesting that restrictive pharmaceutical access policies for clopidogrel following coronary stenting can be associated with increased rates of hospitalisation and death. 13, 24 In future, we also intend to compare clopidogrel and aspirin use post-PCI.
We examined dispensing separately for the 3 months immediately following hospitalisation and the four-to-six month period post-discharge (see Tables b-e in Appendix 3) . Within each 3 month period, the absolute and relative differences across sociodemographic strata were similar to the 6-month data presented in Table 3 .
Irrespective of funding restrictions, however, the proportion of patients with a MPR>0.8 decreased by about 5% from the first 3 months to the 4-to 6 months after discharge across all sociodemographic groups. One factor that may account for the slight reduction in optimal coverage during the second 3-month period post-hospitalisation is the mix of stent types inserted during PCI, although we were unable to determine which stents were used among our study population. Two different types of stent are available: drug eluting stents for which 6 months of clopidogrel therapy was typically indicated, and bare metal stents (used if there is increased risk of bleeding) where 3 months of clopidogrel coverage was more common.
We were concerned that the short supply of clopidogrel issued to some patients whose SA application had not yet been approved at the time of hospital discharge may have contributed to sub-optimal MPRs for these patients, since dispensing directly from hospitals to patients is not captured by the national dispensing database. We could not examine time to first dispensing episode, as our study population was not large enough to allow meaningful stratification by DHB. However, the slightly higher proportion of patients with optimal dispensing in the 3 months immediately post-discharge implies that this short period of unrecorded medication supply is unlikely to have been a significant issue.
The 3-month dispensing data also indicate that health sector publicity accompanying removal of SA criteria on 1 September 2010 is unlikely to have affected clopidogrel dispensing rates. Hospital Subscribe to the NZMJ: http://www.nzma.org.nz/journal/subscribe © NZMA NEW ZEALAND MEDICAL JOURNAL doctors (who likely provided the majority of prescriptions for 3 months of clopidogrel immediately following hospital discharge) would have already been aware of the need for clopidogrel therapy post-PCI. Publicity could, however, have affected prescribing by GPs during the second 3 months after discharge, but the similar (5%) reduction in optimal dispensing between the first and second 3-month periods post-PCI that was observed both during and after funding restrictions implies that health sector notification had little influence on dispensing rates.
Funding restrictions are a necessary cost-containment strategy intended to appropriately manage limited national health resources, and maximise pharmaceutical access for patients that most need it. However, the SA criteria for clopidogrel following PCI restricted access to optimal therapy across all sociodemographic groups of eligible patients. The access barrier resulting from funding restrictions could be minimised in two ways. Firstly, standardisation of the application process is necessary so that authority numbers are routinely available for prescriptions and discharge paperwork prior to hospital discharge. In order to achieve this, PHARMAC needs to engage the Ministry of Health, which provides information technology services to the health sector, regarding provision of a more reliable and user-friendly electronic process.
Development by individual hospital services of a local protocol for SA application that is initiated at a uniform point in the care pathway is also important. For clopidogrel and other anti-platelet therapies, the logical place to commence the application process is the cardiac catheter laboratory. Secondly, PHARMAC should consider more extensive monitoring of medication access than is currently undertaken for those pharmaceuticals where restrictive criteria have been applied. Though logistically labour-intensive, greater monitoring would enable timely identification of possible access issues associated with the SA process so that appropriate remedial action can be initiated.
In conclusion, SA requirements for clopidogrel appeared to have been an access barrier to optimal therapy across all demographic groups of patients who had undergone PCI. However, almost all patients received some clopidogrel therapy in both discharge periods. Removing the requirements did not appear to reduce the small relative disparity in anti-platelet coverage following PCI among Māori and Pacific patients, and the factors contributing to undertreatment in these two ethnic groups require further exploration.
